COMMUNIQUÉS West-GlobeNewswire

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
06/04/2026
Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most serious and underserved supportive-care markets Jericho, New York, April [...]
Aveanna Healthcare Announces Second Annual Aveanna Cares Month of Service
06/04/2026
ATLANTA, April 06, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare (NASDAQ: AVAH ) today announced the second year of Aveanna Cares, the company’s month-long, team-based volunteer initiative dedicated to giving back to the [...]
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
06/04/2026
HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 11,896,750 [...]
Adaptin Bio Shares to be Quoted on the OTCQB Under Ticker Symbol APTN
06/04/2026
CHARLOTTE, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing precision cancer therapeutics enabled by targeted delivery to the [...]
Axe Compute Names Kyle Okamoto President, Adding Deep Infrastructure Systems Expertise to Executive Team
06/04/2026
Okamoto, who helped scale Aethir's decentralized GPU network to 200+ global locations, will lead enterprise growth strategy and execution at Axe Compute PITTSBURGH, April 06, 2026 (GLOBE NEWSWIRE) -- Axe Compute (Nasdaq [...]
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor
06/04/2026
First candidate from Tenvie’s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending doses of TNV262 in healthy volunteers and persons with obesity [...]
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/04/2026
SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High
06/04/2026
Record-breaking output validates aggressive scale-up strategy as Company accelerates toward 10 metric tons per month ANN ARBOR, Mich., April 06, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
06/04/2026
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
06/04/2026
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform
06/04/2026
– Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital [...]
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
06/04/2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” [...]
Beacon Biosignals Upsizes Series B Financing to Over $97 Million
06/04/2026
BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Beacon Biosignals today announced an extension to its Series B financing, bringing the funding round to $97 million and the company’s cumulative funding to over $132 million. [...]
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
06/04/2026
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, [...]
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
06/04/2026
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
06/04/2026
NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory review. NRx [...]
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
06/04/2026
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06 [...]
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
06/04/2026
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed in the open- [...]
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
06/04/2026
Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- [...]

Pages